ライフサイエンスコーパス: equol

1 ual differences in conversion of daidzein to equol.

2 eospecificity of the bacterial production of equol.

3 lity to produce and excrete large amounts of equol.

4 ther classified as person with low- and high-equol.

5 e-metabolizing bacteria and their metabolite equol.

6 ned for their ability to convert daidzein to equol.

7 diet, particularly, daidzein, genistein, and equol.

8 be recapitulated by the daidzein metabolite equol.

9 Eight profiles contained equol.

10 dependent protein synthesis was increased by equol.

11 dehydroequol (31.23 +/- 5.78 muM), 5-hydroxy-equol (125.54 +/- 7.90 muM) and 5-hydroxy-dehydroequol (

12 the production of soy beverages enriched in equol (241.34 +/- 34.56 muM), dehydroequol (31.23 +/- 5.

13 erages fortified with high concentrations of equol, 5-hydroxy-dehydroequol and 5-hydroxy-equol could

14 phytoestrogens, genistein and daidzein, and equol (a daidzein metabolite produced by intestinal micr

15 We previously reported that equol, a metabolite of the soy isoflavone daidzein, may

16 o the potential cardioprotective benefits of equol, a microbial-derived metabolite of the isoflavone

17 ch soy isoflavones (genistein, daidzein, and equol) afford protection against oxidative stress in CVD

18 Equol also increased metastatic cancer cell viability.

19 production of equol, dehydroequol, 5-hydroxy-equol and 5-hydroxy-dehydroequol and to develop soy beve

20 from dihydrodaidzein (DHD), and of 5-hydroxy-equol and 5-hydroxy-dehydroequol from dihydrogenistein (

21 Equol and 5-hydroxy-equol, and their analogous compounds

22 0-50% have the bacteria capable of producing equol and 80-90% harbor O-desmethylangolensin-producing

23 Plasma and urinary [13C]R-equol and [13C]S-equol concentrations were measured by t

24 DHDR was responsible for the production of equol and dehydroequol from dihydrodaidzein (DHD), and o

25 microbial metabolism in animal food sources (equol and enterolactone).

26 y disease, we measured the urinary levels of equol and ISFs.

27 molecular basis for the anticancer action of equol and may partially account for the reported chemopr

28 er the intervention or in BMD change between equol and non-equol producers.

29 ra activities [beta-glucoside hydrolysis and equol and O-desmethylangolensin (O-DMA) production].

30 Equol and O-desmethylangolensin (ODMA) are products of g

31 he soy isoflavone daidzein is metabolized to equol and O-desmethylangolensin (ODMA) by intestinal bac

32 ctors that influence the capacity to produce equol and O-desmethylangolensin are not clearly establis

33 biochanin-A and their mammalian metabolites equol and O-desmethylangolensin in human plasma, urine,

34 es produced by human intestinal bacteria are equol and O-desmethylangolensin.

35 men had detectable concentrations of urinary equol and ODMA (>87.5 ng/mL), respectively, and were cla

36 Equol and ODMA producers reported higher overall physica

37 ons of daidzein intake and gut metabolism to equol and of equol intake from animal products in low-so

38 ced by low or undetectable concentrations of equol and other metabolites, and is maintained by consta

39 was to compare the pharmacokinetics of S-(-)equol and R-(+)equol by using [13C] stable-isotope-label

40 rogen equol occurs as diastereoisomers, S-(-)equol and R-(+)equol, both of which have significant bio

41 abolished by diarylpropionitrile, genistein, equol, and bisphenol A, whereas its coactivation at the

42 ned the interactions of genistein, daidzein, equol, and liquiritigenin with estrogen receptors ERalph

43 ers and mean quantities of dihydrogenistein, equol, and O-desmethylangolensin in the urine of ileosto

44 for isoflavonoids (ie, daidzein, genistein, equol, and O-desmethylangolensin) and lignans (enterodio

45 cell viability and mammosphere formation by equol, and results in a significant down-regulation of e

46 Equol and 5-hydroxy-equol, and their analogous compounds dehydroequol and 5-

47 l half-lives for biochanin A, genistein, and equol are expected to vary on the basis of pH as well as

48 e activities of daidzein and its metabolite, equol, are not understood.

49 g the daidzin and daidzein transformation to equol as a function of pH, temperature and inulin.

50 mers, despite current interest in developing equol as a nutraceutical or pharmaceutical agent.

51 Our studies definitively establish S-equol as the exclusive product of human intestinal bacte

52 urs as diastereoisomers, S-(-)equol and R-(+)equol, both of which have significant biological actions

53 or c-Jun N-terminal kinase, was inhibited by equol but not by daidzein.

54 data, weight increased in subjects producing equol but not in nonproducers.

55 plastic cell transformation was inhibited by equol, but not daidzein, at noncytotoxic concentrations

56 In vitro, equol, but not daidzein, up-regulated eIF4G without affe

57 lignans and isoflavonoids, and in particular equol; but, any effects on human health from such milk c

58 the pharmacokinetics of S-(-)equol and R-(+)equol by using [13C] stable-isotope-labeled tracers to f

59 alpha was decreased in animals treated with equol compared to those treated with 17beta-estradiol.

60 Plasma [13C]equol concentration appearance and disappearance curves

61 ich was significantly associated with plasma equol concentrations (R = -0.36, P = 0.01).

62 nverse association between urinary and serum equol concentrations and breast and prostate cancer risk

63 These results also suggest that equol concentrations in low-soy-consuming populations ma

64 was observed in non-EPs despite mean plasma equol concentrations reaching 3.2 mumol/L.

65 Plasma and urinary [13C]R-equol and [13C]S-equol concentrations were measured by tandem mass spectr

66 cursor daidzein contributed to the increased equol concentrations.

67 umes, were significant correlates of urinary equol concentrations; milk products were more strongly c

68 of ingested daidzin was excreted in urine as equol conjugate in one man and one woman after the first

69 equol, 5-hydroxy-dehydroequol and 5-hydroxy-equol could provide significant health benefits for cons

70 led cellular analyses indicate genistein and equol decrease IL-12/IL-18-induced IFN-gamma production

71 Biochanin A, genistein, and equol degraded relatively slowly by direct photolysis at

72 idzein reductase (DHDR) in the production of equol, dehydroequol, 5-hydroxy-equol and 5-hydroxy-dehyd

73 o and ex vivo pull-down assays revealed that equol directly bound with glutathione S-transferase-MEK1

74 Equol does not affect glycitein bioavailability.

75 Equol dose-dependently attenuated TPA-induced activation

76 Equol dose-dependently inhibited neoplastic transformati

77 f both enantiomers, and the affinity of each equol enantiomer for estrogen receptors was measured.

78 re of equol, to examine whether the S- and R-equol enantiomers are bioavailable, and to ascertain whe

79 nsuming both diets could convert daidzein to equol ex vivo.

80 The amount of urinary equol excreted did not relate to the changes in blood li

81 mpare urinary isoflavonoid excretion between equol excreters and nonexcreters.

82 , which did not differ significantly between equol excreters and nonexcreters.

83 f the subjects were identified previously as equol excreters and the other half as equol nonexcreters

84 These results suggest that equol excretion may be related to the fermentable carboh

85 In women, equol excretion was associated with higher intake of die

86 ot differ between subjects with high and low equol excretion.

87 Dietary sources of equol from animal products have been identified, which h

88 may not reflect the endogenous production of equol from the microbial metabolism of daidzein-an obser

89 uired an ability to exclusively synthesize S-equol from the precursor soy isoflavone daidzein, and it

90 conjugates (daidzein, O-desmethylangolensin, equol, genistein, and glycitein) and two lignans (entero

91 soflavones (daidzein, O-desmethylangolensin, equol, genistein, and glycitein) and two lignans (entero

92 In vitro kinase assays revealed that equol greatly inhibited MEK1, but not Raf1, kinase activ

93 ened subjects (30 men and 30 women) excreted equol (>2000 nmol/d).

94 ever, a single dose of commercially produced equol had no cardiovascular benefits in non-EPs.

95 non-EP, subjects with low and high levels of equol had ORs of 0.51 (95% CI 0.30, 0.84) and 0.67 (95%

96 S-equol has a high affinity for estrogen receptor beta (K(

97 The discovery of equol in human urine more than 2 decades ago and the fin

98 itical in unlocking the vascular benefits of equol in men, and long-term trials should focus on confi

99 tents of daidzein, glycitein, genistein, and equol in milk as well as fresh and mature yogurts was es

100 ion of isoflavones (daidzin and daidzein) to equol in soymilk fermented with Bifidobacterium spp.

101 Moreover, equol increased the polysomal association of mRNAs for p

102 gative (ER-) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were assoc

103 Here we report that equol inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA

104 in intake and gut metabolism to equol and of equol intake from animal products in low-soy-consuming p

105 in low-soy-consuming populations may reflect equol intakes from mammalian milk sources and may not re

106 tinal microflora) are antioxidants in vitro; equol is a particularly good inhibitor of LDL oxidation

107 Equol is an isoflavone (ISF)-derived metabolite by the g

108 ested that the antitumor-promoting effect of equol is due to the inhibition of cell transformation ma

109 eceptor beta (K(i) = 0.73 nmol/L), whereas R-equol is relatively inactive.

110 Therefore, up-regulation of eIF4G by equol may result in increased translation of pro-cancer

111 genistein, total isoflavonoids (TIFLs), and equol (measured by HPLC/photodiode array/mass spectromet

112 Knockdown of eIF4GI also markedly reduces an equol-mediated increase in IRES-dependent mRNA translati

113 Equol might be the critical anti-atherogenic component o

114 sly as equol excreters and the other half as equol nonexcreters.

115 holesterol concentrations than those seen in equol nonproducers.

116 atment period was analyzed for isoflavonoid (equol, O-desmethylangolensin, genistein, and daidzein) a

117 The nonsteroidal estrogen equol occurs as diastereoisomers, S-(-)equol and R-(+)eq

118 ve compounds, namely genistein, daidzein and equol, on the inflammatory responses induced by lipopoly

119 ]equol were higher than those of S-(-)[2-13C]equol or the racemate.

120 Isoflavones were converted into equol- or O-desmethylangolensin- derivatives, whereas an

121 concentrations of genistein (p = 0.0023) and equol (p = 0.006) decreases interleukin (IL)-12/IL-18-in

122 Estrone and equol persisted along the waste disposal route.

123 a support favorable associations between the equol producer (EP) phenotype and cardiometabolic health

124 xyestrone (16alpha-OH) ratio (P < 0.05), and equol-producer status (P < 0.05) compared with CON.

125 ypes and oppositely regulated expression for equol producers (down) and nonproducers (up) after HG su

126 Equol producers (n = 17) had larger reductions in diasto

127 The separation of the group into equol producers (n = 30) and nonproducers (n = 55) showe

128 s, respectively; P < 0.01) compared with non-equol producers (n = 30).

129 data analysis was performed per substudy for equol producers and nonproducers separately.

130 (P = 0.5) in bone calcium retention between equol producers and nonproducers.

131 educed serum LDL cholesterol equally in both equol producers and nonproducers.

132 nflammation-related genes was upregulated in equol producers but downregulated in nonproducers, indep

133 L cholesterol and apolipoprotein A-I only in equol producers compared with reductions in nonproducers

134 Compared with nonproducers, equol producers were more likely (P < or = 0.05) to be H

135 vements in arterial stiffness were observed; equol producers were particularly responsive.

136 However, in equol producers, ~35% of our study population, soy consu

137 ntion or in BMD change between equol and non-equol producers.

138 induced anti-inflammatory gene expression in equol producers.

139 gut microbiome in certain individuals termed equol-producers (EP).

140 t of isoflavones in a soy supplement and the equol-producing ability of the individual on postmenopau

141 specific isoflavone content or the variable equol-producing capacity of individuals.

142 ore effective in maintaining bone density in equol-producing individuals.

143 Participants were randomized by equol-producing phenotype, and data analysis was perform

144 ere influenced by supplement composition and equol-producing phenotype, whereas estrogen-responsive e

145 es after LG supplementation (n = 24) in both equol-producing phenotypes and oppositely regulated expr

146 We analyzed the association between equol-producing status and AC presence, defined as AC sc

147 in postmenopausal women regardless of their equol-producing status, and mixed isoflavones in their n

148 We observed associations between equol production and ethnicity, education, constipation,

149 ng studies: a large cross-sectional study of equol production in humans with a soy challenge, a compa

150 te profile (2-OH:16alpha-OH), and stimulated equol production in postmenopausal women with osteopenia

151 Exploratory analysis suggests that equol production status of subjects on soy may modify ef

152 Other endpoints were not affected by equol production status.

153 Equol production was influenced by pH and temperature in

154 in receptor (Gln223Arg)] and with respect to equol production were investigated.

155 lesteryl ester transfer protein (TaqIB)] and equol production were investigated.

156 The optimum conditions for equol production were pH 8, 30 degrees C and 0.5% inulin

157 ones were observed according to subgroups of equol production.

158 estrone, androstenedione, progesterone, and equol remained detectable in soil at 2 months postapplic

159 S-Equol (SE), a selective estrogen receptor B agonist, has

160 Equol specifically increased the protein expression of I

161 e objective of the study was to show whether equol status determines the effectiveness of soy foods t

162 idzein, genistein, formononetin, naringenin, equol, sum of isoflavones and coumestrol, than CNV and F

163 ex vivo kinase assay also demonstrated that equol suppressed TPA-induced MEK1 kinase activity in JB6

164 availability, and suggests that low doses of equol taken twice daily may be sufficient to achieve bio

165 S-(-)equol, the naturally occurring enantiomer produced by 20

166 idzein, and it is significant that, unlike R-equol, this enantiomer has a relatively high affinity fo

167 Subjects with log10 (urinary equol to daidzein concentration) > - 1.5 were classified

168 fect of providing commercially produced S-(-)equol to non-EPs.

169 assessed the ability of 17beta-estradiol and equol to regulate markers of hippocampal bioenergetic ca

170 were to characterize the exact structure of equol, to examine whether the S- and R-equol enantiomers

171 Similarly, 17beta-estradiol and equol treatment had no effect on mitochondrial fission a

172 ficant effects of either 17beta-estradiol or equol treatment on glycolytic protein expression in the

173 mRNAs that are translationally stimulated by equol treatment.

174 Equol, unlike the soy isoflavones daidzein or genistein,

175 regulator of the cancer-promoting effects of equol via up-regulation of eIF4GI and selective initiati

176 The isoflavone metabolite equol was by far the predominant phytoestrogen species,

177 esponses with the ERbeta-preferring molecule equol was consistent with overall nonresponsiveness.

178 of chiral-phase HPLC and mass spectrometry, equol was isolated from human urine and plasma, and its

179 The elevated eIF4G in response to equol was not associated with eIF4E or 4E-binding protei

180 ly, no benefit of commercially produced S-(-)equol was observed in non-EPs despite mean plasma equol

181 ong those mRNAs translationally increased by equol was the oncogene and eIF4G enhancer, c-Myc.

182 on rates (k(e)) for genistein, daidzein, and equol were 0.1, 0.16, and 0.08 h(-1), respectively, in w

183 es of conjugates of genistein, daidzein, and equol were 24%, 66%, and 28% of the amounts ingested in

184 The pharmacokinetics of S- and R- equol were determined in 3 healthy adults after single-b

185 The pharmacokinetics of racemic (+/-)[2-13C]equol were different from those of the individual enanti

186 ity and fractional absorption of R-(+)[2-13C]equol were higher than those of S-(-)[2-13C]equol or the

187 , the amounts of daidzein and its metabolite equol were significantly higher in samples obtained from

188 n, formononetin, biochanin A, genistein, and equol were studied under simulated solar light and natur

189 turation, the concentrations of daidzein and equol were unaffected, while the glycitein concentration

190 in, and the intestinally derived metabolite, equol, were compared in 4-month-old infants fed exclusiv

191 bolites as O-desmethylangolensin (O-DMA) and equol, whose presence has been linked to health benefits

192 rate assessment, non-EPs consumed 40 mg S-(-)equol with identical vascular measurements performed 2 h